Received May 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Boostrix + possible use before recommended age; This non-serious case was reported by a physician via call center representative and described the occurrence of inappropriate age at vaccine administration in a 7-year-old patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. On an unknown date, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Boostrix + possible use before recommended age). The outcome of the inappropriate age at vaccine administration was not applicable. Additional Information: GSK receipt date: 22-MAY-2025 Doctor called to ask information about approved age of Boostrix being to patients older than 10 years of age. They did not have a specific case at the moment of call but mentioned sometime in her facility they receive 7-year-old patients that need to catch-up on the Dtap vaccine schedule which led to inappropriate age at vaccine administration, and wanted to review information to make clinical decision.